Status:
COMPLETED
Apoptosis Proteins and Endothelial Dysfunction in Patients With Atherosclerosis of Peripheral Arteries
Lead Sponsor:
Ryazan State Medical University
Conditions:
Atherosclerosis
Endothelial Dysfunction
Eligibility:
All Genders
40+ years
Brief Summary
Modern vascular surgery has various options for open and endovascular surgical methods aimed at treating patients with peripheral arterial diseases. Despite the achievements of vascular surgery, the o...
Detailed Description
250 patients will be divided into 5 groups with follow-up period of 2 years. Blood sampling for apoptosis and proliferation (Bcl-2, Bax, Fas, p53, PDGF-BB (platelet derived growth factor BB), VEGF (va...
Eligibility Criteria
Inclusion
- men or women over 40 years of age;
- presence of atherosclerotic peripheral artery disease.
Exclusion
- men or women under 40 years of age;
- chronic lower limb ischemia of a different etiology (disease Burger, aortoarteritis, etc.),
- active cancer or remission period less than 5 years;
- decompensated diabetes mellitus;
- pregnancy or breastfeeding in women
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2023
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04502849
Start Date
January 1 2020
End Date
November 1 2023
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ryazan State Medical University
Ryazan, Russia